Implantable cardioverter-defibrillator deactivation at the end of life: A physician survey

被引:57
作者
Kehey, Amy S. [1 ]
Reid, M. Carrington [2 ]
Miller, David H. [3 ]
Fins, Joseph J. [4 ]
Lachs, Mark S. [2 ]
机构
[1] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA USA
[2] Cornell Univ, Weill Med Coll, Div Geriatr & Gerontol, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, Div Cardiol, New York, NY 10021 USA
[4] Cornell Univ, Weill Med Coll, Div Med Eth, New York, NY 10021 USA
关键词
QUALITY-OF-LIFE; CONGESTIVE-HEART-FAILURE; RECIPIENTS; COMPLICATIONS; DECISIONS; PACEMAKER; VIGNETTES; MANAGEMENT; FREQUENCY; DISEASE;
D O I
10.1016/j.ahj.2008.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Among older adults, implantable cardioverter-defibrillator (ICD) use is increasing. ICD shocks can occur at end of life (EOL) and cause substantial distress, warranting consideration of ICD deactivation discussions. This nationwide physician survey sought to (1) determine if physicians discuss ICD deactivation at the EOL, (2) identify predictors of those discussions, and (3) ascertain physicians' knowledge/attitudes about ICD use. Methods We surveyed 4,876 physicians stratified by specialty (cardiologists, electrophysiologists, general internists, and geriatricians). The mailed survey presented 5 vignettes leg, end-stage chronic obstructive pulmonary disease, advanced dementia) wherein ICD deactivation might be considered and 17 Likert-scaled items. Results Five hundred fifty-eight (12%) physicians returned surveys. Respondents were largely men (77%) and white (69%). Most physicians (56%-83%) said they would initiate deactivation discussions in all 5 vignettes, whereas significantly more (82%-94%) would discuss advance directives and do not resuscitate status. In logistic regression analyses, a history of prior deactivation discussions was an independent predictor of willingness to discuss deactivation (adjusted OR range, 2.8-8.8) in 4 of the 5 vignettes. General internists and geriatricians were less likely than electrophysiologists. to agree that ICD shocks are painful and to distinguish between the ICD's pacing and defibrillator functions. Finally, most physicians believed that informed consent for ICD implantation should include information about deactivation (77%) and endorsed the need for expert guidance in this area (58%). Conclusions Most physicians would discuss ICD deactivation at EOL. The strongest predictor of this was a history of prior discussions. Knowledge about ICDs varies by specialty, and most expressed a desire for more expert guidance about ICD management at EOL. (Am Heart J 2009; 157:702-8.)
引用
收藏
页码:702 / 708
页数:7
相关论文
共 50 条
  • [41] Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
    Uslu, Abdulkadir
    Dogan, Cem
    Duman, Hakan
    Tanboga, Ibrahim Halil
    Askin, Lutfu
    Sevimli, Serdar
    [J]. NORTHERN CLINICS OF ISTANBUL, 2019, 6 (01) : 40 - 47
  • [42] Impact of Implantable Cardioverter-Defibrillator Recalls on Patients' Anxiety, Depression, and Quality of Life
    Undavia, Manish
    Goldstein, Nathan E.
    Cohen, Pilar
    Sinthawanarong, Kamoltip
    Singson, Magdalena
    Bhutani, Divaya
    Munson, Tracey
    Gomes, Joseph Anthony
    Fischer, Avi
    Mehta, Davendra
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2008, 31 (11): : 1411 - 1418
  • [43] Urgent Implantable Cardioverter Defibrillator Deactivation by Unconventional Means
    Beets, Michael Thomas
    Forringer, Edward
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 42 (06) : 941 - 945
  • [44] Deactivation of implantable cardioverter defibrillators towards the end of life: a survey of perceptions and practice among New Zealand clinicians
    Brodie, Tamara
    Landers, Amanda
    Troughton, Richard
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2022, 135 (1554) : 20 - 34
  • [45] Quality of life in patients with a subcutaneous vs. transvenous implantable cardioverter-defibrillator
    Jagosz, Marta
    Jedrzejczyk-Patej, Ewa
    Kowalska, Wiktoria
    Mazurek, Michal
    Warwas, Szymon
    Wiktor, Dominika
    Sokal, Adam
    Kowalski, Oskar
    Lenarczyk, Radostaw
    Sredniawa, Beata
    Kalarus, Zbigniew
    [J]. KARDIOLOGIA POLSKA, 2022, 80 (06) : 679 - 684
  • [46] Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: Results from the NCDR®
    Kramer, Daniel B.
    Kennedy, Kevin F.
    Spertus, John A.
    Normand, Sharon-Lise
    Noseworthy, Peter A.
    Buxton, Alfred E.
    Josephson, Mark E.
    Zimetbaum, Peter J.
    Mitchell, Susan L.
    Reynolds, Matthew R.
    [J]. HEART RHYTHM, 2014, 11 (02) : 216 - 221
  • [47] Deactivation of implantable cardioverter defibrillator in Japanese patients with end-stage heart failure
    Nakazawa, Mayui
    Suzuki, Tsuyoshi
    Shiga, Tsuyoshi
    Suzuki, Atsushi
    Hagiwara, Nobuhisa
    [J]. JOURNAL OF ARRHYTHMIA, 2021, 37 (01) : 196 - 202
  • [48] Psychological and quatity-of-life issues in the young patient with an implantable cardioverter-defibrillator
    DeMaso, David Ray
    Baptista Neto, Louriva
    Hirshberg, Jonathan
    [J]. HEART RHYTHM, 2009, 6 (01) : 130 - 132
  • [49] Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey
    Januszkiewicz, Lukasz
    Barra, Sergio
    Providencia, Rui
    Conte, Giulio
    de Asmundis, Carlo
    Chun, Julian K. R.
    Farkowski, Michal M.
    Guerra, Jose M.
    Marijon, Eloi
    Boveda, Serge
    [J]. EUROPACE, 2022, 24 (05): : 860 - 867
  • [50] Estimates of Implantable Cardioverter-Defibrillator Complications Caveat Emptor
    Anderson, Kelley P.
    [J]. CIRCULATION, 2009, 119 (08) : 1069 - 1071